Corneal and external disorders: Edited by Kristin HammersmithImpact of dry eye disease and treatment on quality of lifeFriedman, Neil Ja,b Author Information aStanford University School of Medicine, Stanford, USA bMid-Peninsula Ophthalmology Medical Group, Palo Alto, California, USA Correspondence to Neil J. Friedman, MD, Mid-Peninsula Ophthalmology Medical Group, 900 Welch Road, Suite 402, Palo Alto, CA 94304, USA Tel: +1 650 324 0056; fax: +1 650 324 1156; e-mail: [email protected] Current Opinion in Ophthalmology 21(4):p 310-316, July 2010. | DOI: 10.1097/ICU.0b013e32833a8c15 Buy Metrics Abstract Purpose of review Recent increased awareness of dry eye disease (DED) by both clinicians and patients has been accompanied by improved recognition that it is a chronic disorder often requiring long-term management. DED, frequently associated with symptoms of discomfort and visual disturbance, also impairs quality of life (QoL), including aspects of physical, social, and psychological functioning. This review summarizes the available research on the impact of DED and its treatment on measures of QoL. Recent findings A relative dearth of data supporting the effectiveness of DED treatments as assessed by QoL measures exists. Both cyclosporine ophthalmic emulsion 0.05% and hydroxypropyl cellulose ophthalmic inserts have been associated with improvements in Ocular Surface Disease Index scores, a disease-specific measure of QoL, and with enhancement of patients' ratings regarding their ability to perform activities of daily living. Summary Because there is a lack of concordance between symptoms and diagnostic measures of DED, QoL measures provide clinicians a valuable tool for assessing the burden of disease as well as response to treatment. Such measures should be employed in clinical practice and in future trials of treatment modalities. © 2010 Lippincott Williams & Wilkins, Inc.